Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis.

摘要: Pulmonary fibrosis is an untreatable, fatal disease characterized by excess deposition of extracellular matrix and inflammation. Although the etiology pulmonary unknown, recent studies have implicated dysregulated immune responses wound healing. Since n-3 polyunsaturated fatty acids (n-3 PUFAs) may beneficially modulate in a variety inflammatory disorders, we investigated therapeutic role docosahexaenoic acid (DHA), single PUFA, lung fibrosis. Intratracheal DHA or PBS was administered to mouse lungs 4 days prior intratracheal bleomycin treatment. Body weight survival were monitored for 21 days. Bronchoalveolar fluid (BALF) cells, cytokines, eicosanoids, histology function determined on serial days (0, 3, 7, 14, 21) after injury. administration mitigated bleomycin-induced Mice pretreated with had significantly less loss mortality The from DHA-pretreated mice markedly pretreatment also protected functional changes associated Bleomycin-induced cellular inflammation BALF tissue blunted pretreatment. These advantageous effects decreased IL-6, LTB4, PGE2 increased IL-10. Our findings demonstrate that DHA, development results suggest further investigations regarding fibrotic injury repair are needed.